Serum tumor markers as predictors for survival in advanced non-small cell lung cancer patients treated with gefitinib

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer et al. · JNCI Journal of the National Cancer Institute · 2000 · 15.7K citations

Medicine, Oncology, Cancer Pharmacology +12

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Thomas J. Lynch, Daphne W. Bell, Raffaella Sordella et al. · New England Journal of Medicine · 2004 · 11.5K citations

Medicine, Oncology, Pharmacology +16

Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group

Glenn J. Bubley, Michael A. Carducci, William L. Dahut et al. · Journal of Clinical Oncology · 1999 · 984 citations

Medicine, Oncology, Genitourinary Oncology +16

Mutations of the Epidermal Growth Factor Receptor Gene Predict Prolonged Survival After Gefitinib Treatment in Patients With Non–Small-Cell Lung Cancer With Postoperative Recurrence

Tetsuya Mitsudomi, Takayuki Kosaka, Hideki Endoh et al. · Journal of Clinical Oncology · 2005 · 958 citations · Full text

Medicine, Molecular Genetics, Oncology +17

Bronchioloalveolar Pathologic Subtype and Smoking History Predict Sensitivity to Gefitinib in Advanced Non–Small-Cell Lung Cancer

Vincent A. Miller, Mark G. Kris, Jyoti D. Patel et al. · Journal of Clinical Oncology · 2004 · 746 citations

Medicine, Oncology, Pharmacology +16